1例乳腺癌患者药物治疗致肺损伤的病例分析与监护  

Case Analysis and Pharmaceutical Care of Lung Injury Caused by Drug Therapy in a Breast Cancer Patient

作　　者：朱秋燕[1] 王金丽[1] 陈伯华[1] Zhu Qiuyan;Wang Jinli;Chen Bohua(Department of Pharmacy,Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu,China)

机构地区：[1]南通大学附属医院药学部

出　　处：《药物流行病学杂志》2019年第11期749-752,共4页Chinese Journal of Pharmacoepidemiology

基　　金：南通市科技计划项目(编号:JCZ18101);南通市药学会-常州四药医院药学科研基金项目(编号:ntyx1815)

摘　　要：1例乳腺癌患者使用3周期多西他赛和曲妥珠单抗(TH方案)治疗后出现活动后气促,后逐渐缓解。第4周期TH方案治疗后再次出现气促,胸部影像学显示肺部损伤,予头孢西丁和地塞米松治疗后好转,地塞米松停药后肺损伤加重。临床药师参与其药物性肺损伤的诊断,推荐使用甲泼尼龙继续规范治疗,患者渐好转出院。药师定期随访,出院25d后肺部病变基本吸收。One patient with breast cancer developed exertional shortness of breath after 3 cycles of docetaxel and trastuzumab treatment, which gradually relieved. When the two drugs were used again in the fourth cycle, shortness of breath recurred. The chest imaging showed lung injury. After treatment with cefoxitin and dexamethasone, the lung injury was improved, which was aggravated again after withdrawal of dexamethasone. Clinical pharmacists participated in the diagnosis of drug-induced lung injury. Methylprednisolone was recommended to continue the standard treatment. The patient gradually improved and was discharged. Pharmacists followed up regularly. Pulmonary lesions of the patient were basically absorbed 25 days after discharge.

关 键 词：乳腺癌 药物性肺损伤 多西他赛 曲妥珠单抗 药品不良反应 药学监护 

分 类 号：R97[医药卫生—药品]